All Issue

2020 Vol.50, Issue 2 Preview Page

Original Article

Genetic Diversity among Varicella-Zoster Virus Vaccine Strains
Se Hwan Kang1
,
Seok Cheon Kim1
,
Jeong Yeol Kim1
,
Chan Hee Lee1*
1Department of Microbiology, Chungbuk National University, Cheongju 28644, Republic of Korea
*Corresponding Author
30 June 2020. pp. 132-139
PDF XML Citation
Abstract

Varicella-zoster virus (VZV) is a causative agent for chickenpox in primary infection and shingles after reactivation from latency. Both varicella and zoster can be prevented by live attenuated vaccines, but the molecular mechanism of attenuation is not clearly understood. In this study, the genome sequences of three varicella vaccine strains were analyzed for the genetic diversity including single nucleotide polymorphism (SNP) and genetic polymorphism. A total of 38 SNPs were identified including 29 substitutions and 9 insertion/deletions. The number of genetically polymorphic sites (GPS) was highest in Varivax and lowest in Varilrix. GPS in the R region including R1, R2, and R3 appeared to be responsible for the genetic polymorphisms in the open reading frame (ORF) 11, 14, and 22 in all three vaccine strains. A relatively large number of GPS were observed in ORF31, 55, and 62, which are known to be essential for virus replication, suggesting that the attenuation of the vaccine strains may be attributed by the diversity of these genes.

Keywords
Varicella-zoster virus
Vaccine
Whole genome sequence
Genetic diversity
References
1
Quinlivan M, Breuer J. Molecular studies of Varicella zoster virus. Rev Med Virol 2006;16:225-50.
10.1002/rmv.50216791838
2
Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013;26:728-43.
10.1128/CMR.00052-1324092852PMC3811230
3
Zerboni L, Sen N, Oliver SL, Arvin AM. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol 2014;12:197-210.
10.1038/nrmicro321524509782PMC4066823
4
Gilden DH, Kleinschmidt-DeMasters BK, Laguardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000;342:635-45.
10.1056/NEJM20000302342090610699164
5
Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288-90.
10.1016/S0140-6736(74)90144-5
6
D'Hondt E, Berge E, Colinet G, Duchene M, Peetermans J. Production and quality control of the Oka-strain live varicella vaccine. Postgrad Med J 1985;61:53-6.
7
Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991;9:643-7.
10.1016/0264-410X(91)90189-D
8
Sohn YM, Park CY, Hwang KK, Woo GJ, Park SY. Safety and immunogenicity of live attenuated varicella virus vaccine (MAV/06 strain). J Korean Ped 1994;37:1405-13.
9
Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002;76:11447-59.
10.1128/JVI.76.22.11447-11459.200212388706PMC136748
10
Tillieux SL, Halsey WS, Thomas ES, Voycik JJ, Sathe GM, Vassilev V. Complete DNA sequences of two oka strain varicella-zoster virus genomes. J Virol 2008;82:11023-44.
10.1128/JVI.00777-0818787000PMC2573284
11
Jeon JS, Won YH, Kim IK, Ahn JH, Shin OS, Kim JH, et al. Analysis of single nucleotide polymorphism among varicella-zoster virus and identification of vaccine-specific sites. Virology 2016;496:277-86.
10.1016/j.virol.2016.06.01727376245
12
Domingo E, Sheldon J, Perales C. Viral quasispecies evolution. Microbiol Mol Biol Rev 2012;76:159-216.
10.1128/MMBR.05023-1122688811PMC3372249
13
Eigen M, Schuster P. The Hypercycle. A principle of natural self-organization. Naturwissenschaften 1977;64:541-65.
10.1007/BF00450633593400
14
Sauder CJ, Vandenburgh KM, Iskow RC, Malik T, Carbone KM, Rubin SA. Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity. Virology 2006;350:48-57.
10.1016/j.virol.2006.01.03516494912
15
Cricca M, Morselli-Labate AM, Venturoli S, Ambretti S, Gentilomi GA, Gallinella G, et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol 2007;106:549-57.
10.1016/j.ygyno.2007.05.00417568661
16
Schmutzhard J, Riedel HM, Wirgart BZ, Grillner L. Detection of herpes simplex virus type 1, herpes simplex virus type 2 and varicella-zoster virus in skin lesions. Comparison of real-time PCR, nested PCR and virus isolation. J Clin Virol 2004;29:120-6.
10.1016/S1386-6532(03)00113-6
17
Hedrick P. Genetics of populations. Jones & Bartlett Learning, 2011.
18
Che X, Oliver SL, Sommer MH, Rajamani J, Reichelt M, Arvin AM. Identification and functional characterization of the Varicella zoster virus ORF11 gene product. Virology 2011;412:156-66.
10.1016/j.virol.2010.12.05521276599PMC3068617
19
Cohen JI, Seidel KE. Absence of varicella-zoster virus (VZV) glycoprotein V does not alter growth of VZV in vitro or sensitivity to heparin. J Gen Virol 1994;75:3087-93.
10.1099/0022-1317-75-11-30877964618
20
González-Motos V, Jürgens C, Ritter B, Kropp KA, Durán V, Larsen O, et al. Varicella zoster virus glycoprotein C increases chemokine-mediated leukocyte migration. PLoS Pathog 2017;13:e1006346.
10.1371/journal.ppat.100634628542541PMC5444840
21
Kwon KM, Ahn JH. Herpesvirus-encoded deubiquitinating proteases and their roles in regulating immune signaling pathways. J Bacteriol Virol 2013;43:244-52.
10.4167/jbv.2013.43.4.244
22
Tyler SD, Peters GA, Grose C, Severini A, Gray MJ, Upton C, et al. Genomic cartography of varicella-zoster virus: a complete genome-based analysis of strain variability with implications for attenuation and phenotypic differences. Virology 2007;359:447-58.
10.1016/j.virol.2006.09.03717069870
23
Khalil MI, Arvin A, Jones J, Ruyechan WT. A sequence within the varicella-zoster virus (VZV) OriS is a negative regulator of DNA replication and is bound by a protein complex containing the VZV ORF29 protein. J Virol 2011;85:12188-200.
10.1128/JVI.05501-1121937644PMC3209344
24
Oliver SL, Brady JJ, Sommer MH, Reichelt M, Sung P, Blau HM, et al. An immunoreceptor tyrosine-based inhibition motif in varicella-zoster virus glycoprotein B regulates cell fusion and skin pathogenesis. Proc Natl Acad Sci U S A 2013;110:1911-6.
10.1073/pnas.121698511023322733PMC3562845
25
Yang E, Arvin AM, Oliver SL. The glycoprotein B cytoplasmic domain lysine cluster is critical for varicella-zoster virus cell-cell fusion regulation and infection. J Virol 2016;91:e01707-16.
10.1128/JVI.01707-1627795427PMC5165221
26
Depledge DP, Kundu S, Jensen NJ, Gray ER, Jones M, Steinberg S, et al. Deep sequencing of viral genomes provides insight into the evolution and pathogenesis of varicella zoster virus and its vaccine in humans. Mol Biol Evol 2014;31:397-409.
10.1093/molbev/mst21024162921PMC3907055
27
Quinlivan M, Breuer J. Clinical and molecular aspects of the live attenuated Oka varicella vaccine. Rev Med Virol 2014;24:254-73.
10.1002/rmv.178924687808
Information
  • Publisher :The Korean Society for Microbiology and The Korean Society of Virology
  • Publisher(Ko) :대한미생물학회‧대한바이러스학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 50
  • No :2
  • Pages :132-139
  • Received Date : 2020-06-11
  • Revised Date : 2020-06-23
  • Accepted Date : 2020-06-23
  • DOI :https://doi.org/10.4167/jbv.2020.50.2.132
Journal Informaiton JOURNAL OF BACTERIOLOGY AND VIROLOGY JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • NRF
  • 임플란트학회 전용 배너
  • KOFST
  • crossref crossmark
  • crossref cited-by
  • crossref funder-registry
  • crosscheck
  • orcid
  • open access
  • ccl
Journal Informaiton Journal Informaiton - close